

Exhibit 2



SPECTRUM Pharmaceuticals

August 30, 2012

Southern California Investor Conference

NASDAQ GS: SPPI



Rajesh C. Shrotriya, MD
Chairman, Chief Executive Officer, and President

n=241, randomized comparative study

Levoleucovorin at equivalent doses* to racemic leucovorin had significantly less myelosuppression ($p=0.03$ Gr 3 /4) with slight improvement in efficacy vs racemic LV

	Overall Response rate	Duration of Response	Median Time to Progression or Death	Median Overall Survival Time
FU/racemic LV	25%	7.2 months	6.25 months	14.5 months
FU/I-LV Pure Isomer	32%	8.0 months	8.0 months	15.0 months

	% FU/LV (n = 122)				% FU/I-LV (n = 119) Pure Isomer			
	Grade				Grade			
Toxicity	1	2	3	4	1	2	3	4
Leukopenia	23	13	3	2	18	7	-	-
Granulocytopenia	15	16	4	4	14	5	2	-

* Racemic LV is a 50:50 mixture of *dextro* (inactive) - & *levo* (active) isomers of leucovorin; an equivalent dose of pure levoleucovorin has double the active *levo*-isomer.

Reference: Scheithauer et al, Journal of Clinical Oncology, Vol 15, No 3 (March), 1997: pp 908-914

